-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Epithelial ovarian cancer (OC) is the leading cause of cancer-related deaths in women worldwide: It is estimated that in 2018, the number of deaths due to OC worldwide was close to 185,000 .
The number of ovarian cancer deaths worldwide due to OC in 2018 is close to 185,000
This study aims to evaluate the addition of human monoclonal anti-PD-L1 antibody atezolizumab to the platinum-based combination with bevacizumab for newly diagnosed stage III-IV Efficacy of ovarian cancer .
To evaluate the addition of human monoclonal anti-PD-L1 antibody atezolizumab to newly diagnosed stage III-IV ovarian cancer in the platinum-based combination with bevacizumab Efficacy
This is a multicenter, placebo-controlled, randomized, double-blind phase III trial that recruited newly diagnosed patients with stage III-IV ovarian cancer who had undergone primary tumor cytoreduction or planned to undergo Neoadjuvant chemotherapy and interval surgery.
PFS and OS in the intention-to-treat population and PD-L1 positive population
PFS and OS in the intention-to-treat population and PD-L1 positive populationFrom March 8, 2017 to March 26, 2019, a total of 1301 patients were recruited.
In the intention-to-treat population, the median progression-free survival of the atuzumab group and the placebo group was 19.
PFS in PD-L1 positive subgroup
PFS in PD-L1 positive subgroupAmong PD-L1 positive patients, the median progression-free survival of the atuzumab group and placebo group was 20.
Among PD-L1 positive patients, the median progression-free survival of the atuzumab group and the placebo group were 20.
In summary, the current analysis results of the study do not support the use of immune checkpoint inhibitors for newly diagnosed ovarian cancer patients .
Newly diagnosed ovarian cancer using immune checkpoint inhibitor use of newly diagnosed ovarian cancer immune checkpoint inhibitors of immune
Original source:
Original source:Kathleen N.
org/doi/full/10.
1200/JCO.
21.
00306" target="_blank" rel="noopener">Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050 / GOG 3015 / ENGOT-OV39) in this message
